Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Male infertility: a biomarker of individual and familial cancer risk

Anabolic steroid–induced hypogonadism: diagnosis and treatment

Akanksha Mehta, M.D., Mark Sigman, M.D. Fertility and Sterility

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Michael M. Alper, M.D. Fertility and Sterility

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Robot-assisted laparoscopy for infertility treatment: current views

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women Hong Zang, M.D.,

Annette Kuhn, M. D. , Doris Bapst, Werner Stadlmayr, M. D

Medical treatment of ectopic pregnancy: a committee opinion

Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing.

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

Oocyte cryopreservation

Efficacy of tibolone as “add-back therapy” in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids Edward.

Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review Seema Menon, M.D., John.

Robert F. Casper, M.D. Fertility and Sterility

Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain Mohamed A. Bedaiwy,

Gadolinium radiologic contrast is a useful alternative for hysterosalpingography in patients with iodine allergy Dorette Noorhasan, M.D., Michael J.

Rahi Victory, M. D. , F. R. C. S. C. , Ghassan M. Saed, Ph. D

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Male infertility: a biomarker of individual and familial cancer risk

Clomiphene citrate at 50: the dawning of assisted reproduction

An employer's experience with infertility coverage: a case study

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

European view of subspecialty training on behalf of the European Society of Human Reproduction and Embryology (ESHRE) Carlos Calhaz-Jorge, M.D., Anis.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Evaluation of diagnostic testis biopsy and the repetition of testicular sperm extraction surgeries in infertility patients Alayman Hussein, M.B.B.C.H.,

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Increased secretion of amylin in women with polycystic ovary syndrome

Eva Balkenende, Taghride Dahhan, M. D. , Fulco van der Veen, M. D, Ph

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists José M. López, M.D., Eveline.

One intrauterine device lost, two found

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

P-425 Fertility and Sterility Volume 86, Issue 3, (September 2006)

Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women Hong Zang, M.D., Kjell Carlström,

Website quality assessment: Mistaking apples for oranges

Effects of hyperglycemia on the differential expression of insulin and insulin-like growth factor-I receptors in human normal peritoneal and adhesion.

L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Current evaluation of amenorrhea

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist

A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human.

Ronald M. Yang, M. D. , Richard A. Fefferman, M. D. , Charles E

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Ahmed Badawy, M.D., Aboubakr.

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

In vitro sildenafil citrate use as a sperm motility stimulant

Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy Eman A. Elgindy,

Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient’s body mass index and the number of larger follicles

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Presentation transcript:

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D., Michael P. Diamond, M.D. Fertility and Sterility Volume 84, Issue 1, Pages 186-190 (July 2005) DOI: 10.1016/j.fertnstert.2005.01.101 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 Rate of glucose uptake during the final hour of euglycemic hyperinsulinemic clamp studies in 10 men pre-GnRH treatment and at the conclusion of 3 months of Depo-Lupron therapy. Chauhan. GnRH agonist effect on insulin action. Fertil Steril 2005. Fertility and Sterility 2005 84, 186-190DOI: (10.1016/j.fertnstert.2005.01.101) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions